232 related articles for article (PubMed ID: 37723497)
1. PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China.
Liu X; Liu Z; Li C; Song X; Wang X; Li S; Yu Z
World J Surg Oncol; 2023 Sep; 21(1):296. PubMed ID: 37723497
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China.
Peng DM; Li J; Qiu JX; Zhao L
World J Surg Oncol; 2024 Apr; 22(1):88. PubMed ID: 38582875
[TBL] [Abstract][Full Text] [Related]
4. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
5. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.
Bilici A; Olmez OF; Kaplan MA; Oksuzoglu B; Sezer A; Karadurmus N; Cubukcu E; Sendur MAN; Aksoy S; Erdem D; Basaran G; Cakar B; Shbair ATM; Arslan C; Sumbul AT; Sezgin Goksu S; Karadag I; Cicin I; Gumus M; Selcukbiricik F; Harputluoglu H; Demirci U
Acta Oncol; 2023 Apr; 62(4):381-390. PubMed ID: 37083566
[TBL] [Abstract][Full Text] [Related]
6. Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study.
O'Shaughnessy J; Robert N; Annavarapu S; Zhou J; Sussell J; Cheng A; Fung A
Breast Cancer Res Treat; 2021 Jun; 187(3):903-913. PubMed ID: 33649981
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study.
Zhou M; Wang S; Wan N; Yuan S; Hu X; Zhou W; Qing B; Liu M; Sun W; Fan P; Wang J; Cao H; Xu H; Dai B; Tang P; Qian L; Zhao X; Xiao J; Zhou H; Hu J; Ding L; Tripodi D; Zdenkowski N; O'Keefe TJ; Sanchez AM; Chen L; Zhang P; Xu F
Ann Transl Med; 2022 Dec; 10(24):1387. PubMed ID: 36660637
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.
Murthy RK; Raghavendra AS; Hess KR; Fujii T; Lim B; Barcenas CH; Zhang H; Chavez-Mac-Gregor M; Mittendorf EA; Litton JK; Giordano SH; Thompson AM; Valero V; Moulder SL; Tripathy D; Ueno NT
Clin Breast Cancer; 2018 Dec; 18(6):e1283-e1288. PubMed ID: 30077429
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
González-Santiago S; Saura C; Ciruelos E; Alonso JL; de la Morena P; Santisteban Eslava M; Gallegos Sancho MI; de Luna A; Dalmau E; Servitja S; Ruiz Borrego M; Chacón JI
Breast Cancer Res Treat; 2020 Nov; 184(2):469-479. PubMed ID: 32876911
[TBL] [Abstract][Full Text] [Related]
10. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
11. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.
Ohzawa H; Sakatani T; Niki T; Yasuda Y; Hozumi Y
Breast Cancer; 2014 Sep; 21(5):563-70. PubMed ID: 23108629
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
[TBL] [Abstract][Full Text] [Related]
13. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015).
Cheng Y; Xiang H; Xin L; Duan X; Liu Y;
Chin Med J (Engl); 2022 Oct; 135(19):2311-2318. PubMed ID: 36535009
[TBL] [Abstract][Full Text] [Related]
15. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy.
Chen H; Gui X; Zhou Z; Su F; Gong C; Li S; Wu W; Rao N; Liu Q; Yao H
Breast; 2024 Jun; 75():103733. PubMed ID: 38615482
[TBL] [Abstract][Full Text] [Related]
16. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
17. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
18. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
[TBL] [Abstract][Full Text] [Related]
19. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
20. Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer.
Xiao Y; Ding J; Ma D; Chen S; Li X; Yu K
Front Immunol; 2022; 13():877825. PubMed ID: 35663978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
